交易 Lyell Immunopharma, Inc. - LYEL CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
- 所有權
交易條件
价差 | 0.05 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Lyell Immunopharma Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Mar 15, 2024 | 2.13 | -0.07 | -3.18% | 2.20 | 2.25 | 2.11 |
Mar 14, 2024 | 2.19 | -0.12 | -5.19% | 2.31 | 2.31 | 2.18 |
Mar 13, 2024 | 2.32 | 0.21 | 9.95% | 2.11 | 2.39 | 2.11 |
Mar 12, 2024 | 2.16 | -0.15 | -6.49% | 2.31 | 2.31 | 2.16 |
Mar 11, 2024 | 2.31 | -0.14 | -5.71% | 2.45 | 2.55 | 2.29 |
Mar 8, 2024 | 2.48 | -0.07 | -2.75% | 2.55 | 2.59 | 2.40 |
Mar 7, 2024 | 2.50 | -0.08 | -3.10% | 2.58 | 2.66 | 2.49 |
Mar 6, 2024 | 2.61 | 0.10 | 3.98% | 2.51 | 2.62 | 2.45 |
Mar 5, 2024 | 2.48 | -0.02 | -0.80% | 2.50 | 2.68 | 2.45 |
Mar 4, 2024 | 2.58 | -0.49 | -15.96% | 3.07 | 3.07 | 2.50 |
Mar 1, 2024 | 3.05 | 0.17 | 5.90% | 2.88 | 3.19 | 2.87 |
Feb 29, 2024 | 2.91 | 0.20 | 7.38% | 2.71 | 3.03 | 2.62 |
Feb 28, 2024 | 2.82 | 0.09 | 3.30% | 2.73 | 2.91 | 2.71 |
Feb 27, 2024 | 2.82 | 0.09 | 3.30% | 2.73 | 2.82 | 2.55 |
Feb 26, 2024 | 2.59 | 0.22 | 9.28% | 2.37 | 2.59 | 2.33 |
Feb 23, 2024 | 2.37 | -0.01 | -0.42% | 2.38 | 2.44 | 2.32 |
Feb 22, 2024 | 2.41 | 0.20 | 9.05% | 2.21 | 2.44 | 2.21 |
Feb 21, 2024 | 2.26 | 0.24 | 11.88% | 2.02 | 2.26 | 2.02 |
Feb 20, 2024 | 2.09 | 0.23 | 12.37% | 1.86 | 2.09 | 1.86 |
Feb 16, 2024 | 1.84 | 0.02 | 1.10% | 1.82 | 1.91 | 1.82 |
Lyell Immunopharma, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
沒有活動安排 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
總收入 | 84.683 | 10.65 | 7.756 | 0.657 |
收入 | 84.683 | 10.65 | 7.756 | 0.657 |
總營業費用 | 276.741 | 261.873 | 219.693 | 102.746 |
銷售/一般/行政費用,總計 | 117.307 | 89.057 | 46.881 | 39.151 |
研究與開發 | 164.318 | 134.98 | 182.243 | 63.595 |
Other Operating Expenses, Total | -9.884 | 1.089 | -9.431 | 0 |
營業收入 | -192.058 | -251.223 | -211.937 | -102.089 |
利息收入(費用),非經營淨值 | 5.986 | 0.909 | 5.939 | 8.121 |
其他,淨值 | 2.954 | 0.095 | 1.526 | -35.409 |
稅前淨收入 | -183.118 | -250.219 | -204.472 | -129.377 |
稅後淨收入 | -183.118 | -250.219 | -204.472 | -129.377 |
未計算非常項目前的淨收益 | -183.118 | -250.219 | -204.472 | -129.377 |
淨收入 | -183.118 | -250.219 | -204.472 | -129.377 |
普通股股東可獲收益 (不含非經常性項目) | -183.118 | -250.219 | -204.472 | -129.377 |
普通股股東可獲收益 (含非經常性項目) | -183.118 | -250.219 | -204.472 | -129.377 |
攤薄淨收入 | -183.118 | -250.219 | -204.472 | -129.377 |
攤薄後加權平均股 | 249.567 | 242.738 | 242.83 | 242.83 |
扣除特別項目的每股攤薄盈利 | -0.73374 | -1.03082 | -0.84204 | -0.53279 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
每股正常攤薄盈利 | -0.71371 | -0.87943 | -0.84204 | -0.53279 |
異常費用(收入) | 5 | 36.747 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0.027 | 0.065 | 48.386 | 0.003 | 35.741 |
收入 | 0.027 | 0.065 | 48.386 | 0.003 | 35.741 |
總營業費用 | 68.855 | 72.621 | 63.17 | 71.44 | 73.002 |
銷售/一般/行政費用,總計 | 19.03 | 19.279 | 26.348 | 26.084 | 30.454 |
研究與開發 | 47.471 | 46.338 | 45.339 | 39.166 | 40.132 |
Other Operating Expenses, Total | -0.569 | -2.996 | -8.517 | 1.19 | 2.416 |
營業收入 | -68.828 | -72.556 | -14.784 | -71.437 | -37.261 |
利息收入(費用),非經營淨值 | 5.264 | 4.497 | 3.453 | 1.17 | 0.938 |
其他,淨值 | -0.326 | 1.1 | 2.934 | 0.013 | |
稅前淨收入 | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
稅後淨收入 | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
未計算非常項目前的淨收益 | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
淨收入 | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
普通股股東可獲收益 (不含非經常性項目) | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
普通股股東可獲收益 (含非經常性項目) | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
攤薄淨收入 | -63.89 | -66.959 | -8.397 | -70.254 | -36.323 |
攤薄後加權平均股 | 250.204 | 249.591 | 259.414 | 248.32 | 246.312 |
扣除特別項目的每股攤薄盈利 | -0.25535 | -0.26827 | -0.03237 | -0.28292 | -0.14747 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.24367 | -0.22821 | -0.03237 | -0.26278 | -0.14747 |
異常費用(收入) | 2.923 | 10 | 0 | 5 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
流動資産總額 | 651.295 | 626.286 | 617.547 | 440.259 |
現金和短期投資 | 640.152 | 614.794 | 612.619 | 436.049 |
現金等價物 | 123.554 | 293.828 | 140.406 | 96.674 |
短期投資 | 516.598 | 320.966 | 472.213 | 339.375 |
預付的費用 | 11.143 | 11.492 | 4.928 | 4.21 |
總資産 | 937.561 | 1127.41 | 908.28 | 555.631 |
物業/廠房/設備,總計 - 淨額 | 166.265 | 166.639 | 124.055 | 43.705 |
物業/廠房/設備,總計 - 總額 | 198.649 | 181.152 | 129.159 | 44.961 |
累計折舊,總計 | -32.384 | -14.513 | -5.104 | -1.256 |
長期投資 | 115.041 | 330.532 | 163.443 | 68.983 |
其他長期資産,總計 | 4.96 | 3.949 | 3.235 | 2.684 |
流動負債總額 | 37.028 | 46.738 | 49.285 | 22.045 |
應付賬款 | 3.917 | 3.207 | 9.396 | 2.844 |
預提費用 | 26.403 | 27.588 | 26.952 | 13.019 |
應付票據/短期債務 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 6.708 | 15.943 | 12.937 | 6.182 |
負債總額 | 104.309 | 197.619 | 189.84 | 147.576 |
長期債務總額 | 0 | 0 | 0 | 0 |
其他負債,總計 | 67.281 | 150.881 | 140.555 | 125.531 |
總權益 | 833.252 | 929.787 | 718.44 | 408.055 |
Redeemable Preferred Stock | 0 | 0 | 1010.97 | 519.163 |
普通股 | 0.025 | 0.024 | 0.002 | 0.001 |
額外實收資本 | 1608.31 | 1515.75 | 41.357 | 18.108 |
留存收益(累計赤字) | -767.48 | -584.362 | -334.143 | -129.671 |
其他權益,總計 | -7.599 | -1.623 | 0.256 | 0.454 |
總負債和股東權益 | 937.561 | 1127.41 | 908.28 | 555.631 |
已發行普通股總數 | 249.567 | 242.738 | 242.83 | 242.83 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 586.854 | 606.41 | 624.398 | 651.295 | 659.745 |
現金和短期投資 | 575.431 | 595.748 | 612.769 | 640.152 | 648.132 |
現金等價物 | 286.214 | 224.372 | 109.426 | 123.554 | 116.311 |
短期投資 | 289.217 | 371.376 | 503.343 | 516.598 | 531.821 |
預付的費用 | 11.423 | 10.662 | 11.629 | 11.143 | 11.613 |
總資産 | 794.989 | 835.354 | 880.45 | 937.561 | 977.269 |
物業/廠房/設備,總計 - 淨額 | 148.699 | 155.189 | 160.99 | 166.265 | 169.811 |
長期投資 | 54.73 | 68.953 | 90.179 | 115.041 | 144.52 |
其他長期資産,總計 | 4.706 | 4.802 | 4.883 | 4.96 | 3.193 |
流動負債總額 | 35.064 | 34.39 | 30.797 | 37.028 | 51.217 |
應付賬款 | 4.365 | 5.805 | 5.733 | 3.917 | 4.795 |
預提費用 | 29.652 | 24.832 | 22.416 | 28.755 | 23.568 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 1.047 | 3.753 | 2.648 | 4.356 | 22.854 |
負債總額 | 97.416 | 98.499 | 96.624 | 104.309 | 157.243 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 62.352 | 64.109 | 65.827 | 67.281 | 106.026 |
總權益 | 697.573 | 736.855 | 783.826 | 833.252 | 820.026 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
普通股 | 0.025 | 0.025 | 0.025 | 0.025 | 0.025 |
額外實收資本 | 1647.91 | 1637.54 | 1622.12 | 1608.31 | 1589.08 |
留存收益(累計赤字) | -949.182 | -898.329 | -834.439 | -767.48 | -759.083 |
其他權益,總計 | -1.181 | -2.379 | -3.879 | -7.599 | -9.996 |
總負債和股東權益 | 794.989 | 835.354 | 880.45 | 937.561 | 977.269 |
已發行普通股總數 | 251.869 | 251.027 | 249.609 | 249.567 | 249.24 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
净收入/起跑线 | -183.118 | -250.219 | -204.472 | -129.377 |
经营活动产生的现金 | -169.555 | -126.249 | -160.874 | 39.474 |
经营活动产生的现金 | 18.02 | 13.624 | 4.294 | 1.256 |
非现金物品 | 77.558 | 106.331 | 39.64 | 56.787 |
营运资金的变化 | -82.015 | 4.015 | -0.336 | 110.808 |
投资活动产生的现金 | -11.54 | -121.573 | -273.516 | -422.433 |
资本支出 | -24.276 | -65.504 | -51.481 | -16.047 |
其他投资现金流量项目,总计 | 12.736 | -56.069 | -222.035 | -406.386 |
融资活动产生的现金 | 10.635 | 401.244 | 476.79 | 351.156 |
股票的发行(报废),净额 | 11.096 | 401.244 | 476.79 | 351.156 |
现金净变化 | -170.46 | 153.422 | 42.4 | -31.803 |
融资现金流项目 | -0.461 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -66.959 | -183.118 | -174.721 | -104.467 | -68.144 |
Cash From Operating Activities | -46.212 | -169.555 | -129.288 | -92.185 | -47.852 |
Cash From Operating Activities | 5.027 | 18.02 | 12.979 | 8.358 | 4.187 |
Non-Cash Items | 20.031 | 77.558 | 71.076 | 44.295 | 18.494 |
Changes in Working Capital | -4.311 | -82.015 | -38.622 | -40.371 | -2.389 |
Cash From Investing Activities | 32.154 | -11.54 | -58.188 | -1.103 | -26.122 |
Capital Expenditures | -1.533 | -24.276 | -19.694 | -16.903 | -9.733 |
Other Investing Cash Flow Items, Total | 33.687 | 12.736 | -38.494 | 15.8 | -16.389 |
Cash From Financing Activities | -0.069 | 10.635 | 9.772 | 5.012 | 2.555 |
Issuance (Retirement) of Stock, Net | 0 | 11.096 | 10.139 | 5.012 | 2.555 |
Net Change in Cash | -14.127 | -170.46 | -177.704 | -88.276 | -71.419 |
Financing Cash Flow Items | -0.069 | -0.461 | -0.367 |
投資者名稱 | 投資者類型 | 流通股百分比 | 持有股份 | 股份變動 | 持有日期 | 換手率 |
---|---|---|---|---|---|---|
ARCH Venture Partners | Venture Capital | 14.5055 | 36412716 | 0 | 2023-03-31 | LOW |
GSK plc | Corporation | 12.0518 | 30253189 | 0 | 2023-03-31 | LOW |
MWG Management, Ltd. | Investment Advisor | 8.0319 | 20162332 | 0 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.713 | 16851453 | 4092330 | 2023-06-30 | LOW |
Apoletto Ltd | Investment Advisor | 6.0129 | 15093969 | 0 | 2022-09-30 | |
Orland Properties Ltd | Investment Advisor | 6.0129 | 15093969 | 0 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.5021 | 11301579 | 764502 | 2023-06-30 | LOW |
Foresite Capital Management, LLC | Private Equity | 3.8641 | 9700000 | -300000 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 3.2373 | 8126378 | 4192340 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.4584 | 6171245 | -1750007 | 2023-06-30 | LOW |
Alphabet, Inc. | Venture Capital | 2.3365 | 5865125 | 0 | 2023-06-30 | LOW |
Bishop (Hans Edgar) | Individual Investor | 1.8666 | 4685614 | 0 | 2023-03-31 | LOW |
Klausner Richard | Individual Investor | 1.5762 | 3956734 | -11100 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3448 | 3375828 | 187393 | 2023-06-30 | LOW |
MIC Capital Management UK LLP | Investment Advisor | 1.2192 | 3060569 | 0 | 2023-06-30 | LOW |
SC China Holding Ltd | Investment Advisor | 1.2134 | 3045997 | 0 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.1411 | 2864448 | -65757 | 2023-06-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.547 | 1373218 | -18190 | 2023-06-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.5185 | 1301656 | 47027 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4589 | 1152009 | 12535 | 2023-06-30 | LOW |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Lyell Immunopharma, Inc. Company profile
关于 Lyell Immunopharma Inc.
Lyell Immunopharma, Inc是一家T细胞重编程公司。 该公司提供T细胞来治疗实体瘤患者。 其技术旨在以目标和不可知的方式应用于嵌合抗原受体(CAR)、肿瘤浸润淋巴细胞(TIL)和T细胞受体(TCR)疗法,以改善T细胞的特性,根除实体瘤。 它建立了一个多模式的产品管道,横跨有未满足需求的实体瘤适应症,并预期有研究性新药申请(IND)。 它提供Gen-R和Epi-R技术平台。 其Gen-R是其体内外基因重编程技术,以克服T细胞枯竭。 其Epi-R是一种体外表观遗传重编程技术,以创造具有持久干性的T细胞群。 Epi-R旨在生成具有这种持久干性特性的T细胞群。 该公司利用其Gen-R和Epi-R技术平台,开发多模式的产品管道。
Industry: | Bio Therapeutic Drugs |
201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球580,000万多名交易者的一份子,选择利用Capital.com进行交易吧。